Equities

Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.70
  • Today's Change0.01 / 1.45%
  • Shares traded41.85k
  • 1 Year change-21.35%
  • Beta0.4890
Data delayed at least 20 minutes, as of Nov 08 2024 04:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform0
Hold0
Sell1
Strong Sell0

Share price forecast in AUD

The one analyst offering a 12 month price target expects Proteomics International LaboratoriesLtd share price to fall to 0.50 in the next year from the last price of 0.70.
High-28.6%0.50
Med-28.6%0.50
Low-28.6%0.50

Earnings history & estimates in AUD

Proteomics International LaboratoriesLtd reported annual 2024 losses of -0.051 per share on Aug 22, 2024.
Average growth rate-2.00%
More ▼

Revenue history & estimates in AUD

Proteomics International Laboratories Ltd had revenues for the full year 2024 of 3.57m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.